Marianne P. Allen

Array ( [id] => 17362673 [patent_doc_number] => 11229681 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-25 [patent_title] => Dominant-negative FGF2 antagonists [patent_app_type] => utility [patent_app_number] => 16/033007 [patent_app_country] => US [patent_app_date] => 2018-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 14 [patent_no_of_words] => 16363 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16033007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13518727 [patent_doc_number] => 20180310906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS [patent_app_type] => utility [patent_app_number] => 16/028235 [patent_app_country] => US [patent_app_date] => 2018-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16028235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19181053 [patent_doc_number] => 11987635 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-21 [patent_title] => Anti-4-1BB antibodies and methods of making and using thereof [patent_app_type] => utility [patent_app_number] => 16/615119 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 7 [patent_no_of_words] => 10150 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16615119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14639117 [patent_doc_number] => 10364291 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-30 [patent_title] => Human anti-VEGFR-2/KDR antibodies [patent_app_type] => utility [patent_app_number] => 16/008744 [patent_app_country] => US [patent_app_date] => 2018-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 13 [patent_no_of_words] => 9306 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16008744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17586592 [patent_doc_number] => 11324834 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => Insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome [patent_app_type] => utility [patent_app_number] => 16/006561 [patent_app_country] => US [patent_app_date] => 2018-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 14 [patent_no_of_words] => 21239 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16006561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16072459 [patent_doc_number] => 20200190216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => MMP13 BINDING IMMUNOGLOBULINS [patent_app_type] => utility [patent_app_number] => 16/617869 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37335 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16190832 [patent_doc_number] => 20200231681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => A NOVEL ANTI-C-MET ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/616345 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17377038 [patent_doc_number] => 11235027 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing [patent_app_type] => utility [patent_app_number] => 15/981642 [patent_app_country] => US [patent_app_date] => 2018-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 16 [patent_no_of_words] => 11295 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15981642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963163 [patent_doc_number] => 20200165333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => FULLY HUMANIZED ANTI-PLATELET FACTOR 4 ANTIBODIES THAT TREAT HEPARIN-INDUCED THROMBOCYTOPENIA [patent_app_type] => utility [patent_app_number] => 16/611613 [patent_app_country] => US [patent_app_date] => 2018-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17177393 [patent_doc_number] => 11154622 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-26 [patent_title] => Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies [patent_app_type] => utility [patent_app_number] => 15/978036 [patent_app_country] => US [patent_app_date] => 2018-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 44 [patent_no_of_words] => 34846 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15978036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13606965 [patent_doc_number] => 20180355031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS [patent_app_type] => utility [patent_app_number] => 15/975834 [patent_app_country] => US [patent_app_date] => 2018-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28327 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15975834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012817 [patent_doc_number] => 20200181251 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => LRRC33 INHIBITORS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/611029 [patent_app_country] => US [patent_app_date] => 2018-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17953500 [patent_doc_number] => 11479591 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-25 [patent_title] => Recombinant modified fibroblast growth factors and therapeutic uses thereof [patent_app_type] => utility [patent_app_number] => 16/611182 [patent_app_country] => US [patent_app_date] => 2018-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 34371 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17587713 [patent_doc_number] => 11325969 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => FGL2 antibodies and binding fragments thereof and uses thereof [patent_app_type] => utility [patent_app_number] => 16/642685 [patent_app_country] => US [patent_app_date] => 2018-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 19 [patent_no_of_words] => 18264 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16642685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15451323 [patent_doc_number] => 20200038485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => METHOD OF STIMULATING ASYMMETRIC DIVISION OF SATELLITE STEM CELLS [patent_app_type] => utility [patent_app_number] => 16/606834 [patent_app_country] => US [patent_app_date] => 2018-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9631 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13371973 [patent_doc_number] => 20180237527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => ANTIBODY FRAGMENTS, COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/952513 [patent_app_country] => US [patent_app_date] => 2018-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8838 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15952513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16105639 [patent_doc_number] => 10695404 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-30 [patent_title] => Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs [patent_app_type] => utility [patent_app_number] => 15/952516 [patent_app_country] => US [patent_app_date] => 2018-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 31 [patent_no_of_words] => 49481 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15952516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13357305 [patent_doc_number] => 20180230192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => FIBROBLAST GROWTH FACTOR MUTANTS HAVING IMPROVED FUNCTIONAL HALF-LIFE AND METHODS OF THEIR USE [patent_app_type] => utility [patent_app_number] => 15/949802 [patent_app_country] => US [patent_app_date] => 2018-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30635 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15949802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16809516 [patent_doc_number] => 20210132070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => SEROLOGICAL BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG CANCER [patent_app_type] => utility [patent_app_number] => 16/499950 [patent_app_country] => US [patent_app_date] => 2018-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -171 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16499950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18356073 [patent_doc_number] => 11644468 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-09 [patent_title] => Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule [patent_app_type] => utility [patent_app_number] => 16/498557 [patent_app_country] => US [patent_app_date] => 2018-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 13412 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498557 [rel_patent_id] =>[rel_patent_doc_number] =>)